American Century Companies Inc. increased its holdings in Haemonetics Co. (NYSE:HAE) by 288.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 193,013 shares of the medical instruments supplier’s stock after acquiring an additional 143,309 shares during the quarter. American Century Companies Inc.’s holdings in Haemonetics were worth $11,210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of HAE. Janney Montgomery Scott LLC increased its stake in Haemonetics by 3.8% during the 3rd quarter. Janney Montgomery Scott LLC now owns 51,256 shares of the medical instruments supplier’s stock valued at $2,300,000 after purchasing an additional 1,879 shares in the last quarter. Rhumbline Advisers increased its stake in Haemonetics by 2.1% during the 3rd quarter. Rhumbline Advisers now owns 104,669 shares of the medical instruments supplier’s stock valued at $4,696,000 after purchasing an additional 2,145 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in Haemonetics by 3.7% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 589,379 shares of the medical instruments supplier’s stock valued at $26,446,000 after purchasing an additional 20,925 shares in the last quarter. Boston Advisors LLC increased its stake in Haemonetics by 83.8% during the 3rd quarter. Boston Advisors LLC now owns 50,825 shares of the medical instruments supplier’s stock valued at $2,281,000 after purchasing an additional 23,180 shares in the last quarter. Finally, TCW Group Inc. bought a new stake in Haemonetics during the 3rd quarter valued at about $457,000.
In other news, Director Mark W. Kroll sold 7,118 shares of Haemonetics stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $63.00, for a total value of $448,434.00. Following the completion of the sale, the director now directly owns 33,881 shares in the company, valued at $2,134,503. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.20% of the company’s stock.
A number of analysts have weighed in on HAE shares. Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $52.00 price objective for the company in a research note on Wednesday, October 25th. Barrington Research raised their price objective on shares of Haemonetics from $48.00 to $57.00 and gave the company an “outperform” rating in a research note on Wednesday, November 8th. Craig Hallum restated a “hold” rating and set a $50.00 price objective (up from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. Morgan Stanley raised their price objective on shares of Haemonetics from $43.00 to $51.00 and gave the company an “equal weight” rating in a research note on Thursday, November 9th. Finally, Raymond James Financial upgraded shares of Haemonetics from an “underperform” rating to a “market perform” rating in a research note on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $71.33.
Shares of Haemonetics Co. (HAE) opened at $69.56 on Friday. Haemonetics Co. has a 12 month low of $37.20 and a 12 month high of $72.33. The company has a market cap of $3,756.83, a P/E ratio of -204.58, a PEG ratio of 3.48 and a beta of 1.06. The company has a quick ratio of 1.33, a current ratio of 1.82 and a debt-to-equity ratio of 0.14.
Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.18. Haemonetics had a negative net margin of 1.94% and a positive return on equity of 12.39%. The firm had revenue of $234.04 million during the quarter, compared to analyst estimates of $227.79 million. During the same period in the previous year, the business posted $0.43 earnings per share. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. research analysts anticipate that Haemonetics Co. will post 1.86 EPS for the current fiscal year.
Haemonetics announced that its Board of Directors has approved a share repurchase program on Tuesday, February 6th that authorizes the company to repurchase $260.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/02/18/american-century-companies-inc-raises-position-in-haemonetics-co-hae.html.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.